SMO
Protein smoothened
As of the edition of 20 October 2026, SMO (protein smoothened, UniProt Q99835) has 9 drugs tested at it and 12 companies on the list, 5 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q99835
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 15
- Disease areas
- Cancer; Blood and lymph; Digestive system; Lungs and airways; Skin and connective tissue; Hormones; Immune system; Bones, joints and muscles
- Registered trials of its drugs
- 184
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vismodegib | Marketed | Phase 4 | Ends 2028 |
| Sonidegib | Marketed | Phase 4 | Ends 2036 |
| Glasdegib | Marketed | Phase 3 | Ends 2036 |
| Taladegib | Active | Phase 2 | none listed |
| Patidegib | Stopped | Phase 3 | none listed |
| BMS-833923 | Went quiet | Phase 2 | none listed |
| LEQ506 | Went quiet | Phase 1 | none listed |
| TAK-441 | Went quiet | Phase 1 | none listed |
| ZSP1602 | Went quiet | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 2 |
| Engaged | 3 |
| Undetermined | 2 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Bristol Myers Squibb | Route A |
| Sol-Gel Technologies | Route A |
The other 9 companies at SMO
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at SMO, ranked, with the facts behind eachRequest access. Nothing is shown until you do.